Literature DB >> 22303826

US FDA/EMA harmonization of their bioanalytical guidance/guideline and activities of the Global Bioanalytical Consortium.

Fabio Garofolo1, Josée Michon, Virginie Leclaire, Brian Booth, Stephen Lowes, C T Viswanathan, Jan Welink, Sam Haidar, Leonardo de Souza Teixeira, Daniel Tang, Binodh Desilva.   

Abstract

The 2011 annual conference of the American Association of Pharmaceutical Scientists, held in Washington DC, USA, hosted a roundtable entitled: 'Update of the US FDA/European Medicines Agency (EMA) harmonization of their bioanalytical guidance - Global Bioanalytical Consortium activity and impact on small and large molecules.' The roundtable was initiated with a presentation from CT Viswanathan on the history of the revision of the FDA guideline on bioanalytical method validation. It was followed by a presentation by Jan Welink who presented an update on the final European Medicines Agency guideline on bioanalytical method validation with relevance to ongoing harmonization efforts. The final presentation was by Fabio Garofolo on the progress of the Global Bioanalytical Consortium harmonization teams for small and large molecules. Brian Booth and Sam Haidar of the FDA updated the audience on the status of the revision of the FDA bioanalytical guidance. The roundtable was moderated by Stephen Lowes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22303826     DOI: 10.4155/bio.12.1

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  1 in total

1.  Quantification of neomangiferin in rat plasma by liquid chromatography-tandem mass spectrometry and its application to bioavailability study.

Authors:  Bo Yang; Zhirui Liu; Shenglan Shang; Xiaojian Qin; Peiyuan Xia
Journal:  J Pharm Anal       Date:  2016-03-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.